Press Releases

11/04/2016 Fifth country opens recruitment in the global pivotal Phase 3 Trial of the immunotherapy Tedopi® with initiation in Hungary
04/04/2016 OSE Pharma to Join Workshop “Phase I: An inflection point in drug development and value generation” at BIO-Europe Spring® 2016
20/09/2016 OSE Immunotherapeutics to present Atalante 1 at the WLCL 2016
27/12/2016 OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
28/11/2016 OSE Immunotherapeutics appoints Dr. Frédérique Corallo, as Chief Medical Officer
17/11/2016 OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104
15/11/2016 Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
15/11/2016 OSE Immunotherapeutics Awarded First Prize and "Listed Company" Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest
24/10/2016 OSE Immunotherapeutics to present at 2016 MedStart Up Days
04/10/2016 OSE Immunotherapeutics to present the preclinical data of its new checkpoint inhibitor Effi-DEM
15/09/2016 OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director
08/09/2016 OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results
30/08/2016 OSE Immunotherapeutics will present at the Rodman & Renshaw 18th Annual Global Investment Conference
12/07/2016 OSE Immunotherapeutics presents new preclinical efficacy results with Effi-DEM
05/07/2016 OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen
27/06/2016 OSE Immunotherapeutics presents significant preclinical efficacy results for Effi-7
20/06/2016 OSE Immunotherapeutics presents significant preclinical results for new generation checkpoint inhibitor, Effi-DEM
09/06/2016 Publication of the 2015 Reference Document
1 2 3 4 5 6 7 8 9 10 11 12

To receive OSE Immunotherapeutics’ latest news